Skip to content
PeptideTech
Cart

Home / Research library / CagriSema

Blends

CagriSema: molecular data, studies & sources

CagriSema is catalogued here as a combination of ingredients. This profile brings together the molecular source record, selected indexed publications and available supplier comparisons. Evidence for a named substance does not authenticate a commercial product.

Compiled by PeptideTech Editors · Sources checked · Selected bibliography, not a systematic review

Molecular formula, weight & structure

A blend is not one molecule

This is a combination of separate ingredients, not a single molecule. Ingredient molecular weights cannot be added to describe a vial or establish evidence for the blend.

MF: not assigned · MW: not assigned · Structure: not assigned

Catalogued ingredients: Cagrilintide · Semaglutide. The supplier must specify the amount and identity of each ingredient.

Registered clinical trials

Studies registered on ClinicalTrials.gov that list CagriSema as an intervention. Studies that only measure the molecule as a biomarker, or use it only as a comparator or background arm for another drug, are excluded. A registration describes a planned or completed protocol; it does not report a result. Active studies are listed first.

29 registered studies matched, 11 currently active or recruiting.

By highest phase
Phase 3 · 19Phase 2 · 4Phase 1 · 6
By registry status
Completed · 16Recruiting · 6Active Not Recruiting · 5Withdrawn · 2
StudyPhase · statusConditionsSponsor · size
Research Study on How People With Type 2 Diabetes Tolerate Switching From Semaglutide to CagrisemaNCT07817251 · start 2026-09-16 · primary completion 2027-06-09Phase 3RecruitingDiabetes Mellitus, Type 2Novo Nordisk A/S210 participants
A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in Children and Adolescents With Type 2 DiabetesNCT07282613 · start 2026-08-04 · primary completion 2029-09-07Phase 3RecruitingDiabetes Mellitus, Type 2Novo Nordisk A/S80 participants
A Research Study to Look at How Two Different Doses of CagriSema and One Dose of Semaglutide Help People Living With Obesity With or Without Type 2 Diabetes Lose WeightNCT07564414 · start 2026-05-21 · primary completion 2028-02-23Phase 3RecruitingObesity · Type 2 DiabetesNovo Nordisk A/S2500 participants
Understanding the Effect of CagriSema, Cagrilintide, and Semaglutide on Muscle Health (Role of Amylin Signature in Muscle Health)NCT07527195 · start 2026-04-10 · primary completion 2028-04-28Phase 1RecruitingObesityNovo Nordisk A/S100 participants
A Research Study on How Well Cagrilintide and CagriSema Work in Children and Adolescents With Excess Body WeightNCT07253285 · start 2026-01-08 · primary completion 2030-03-20Phase 3RecruitingOverweight · ObesityNovo Nordisk A/S460 participants
A Study to See How Metabolism is Influenced by Weight Loss Due to Intervention With Cagrilintide and Semaglutide Compared to DietNCT07184086 · start 2025-09-26 · primary completion 2027-10-12Phase 1Active Not RecruitingObesityNovo Nordisk A/S80 participants
The Role of the Amylin Analogue Cagrilintide in Bone MetabolismNCT07010432 · start 2025-06-12 · primary completion 2028-05-03Phase 1RecruitingObesityNovo Nordisk A/S144 participants
A Research Study to Look at How Well CagriSema Helps People Living With Obesity Lose Weight and Maintain Weight Loss in the Long-termNCT07011667 · start 2025-06-03 · primary completion 2027-03-01Phase 3Active Not RecruitingObesityNovo Nordisk A/S609 participants
A Research Study to Look Into the Long-term Effect on Weight Loss of CagriSema in People With ObesityNCT06780449 · start 2025-02-10 · primary completion 2028-08-28Phase 3Active Not RecruitingObesityNovo Nordisk A/S400 participants
REDEFINE 3: A Research Study to See the Effects of CagriSema in People Living With Diseases in the Heart and Blood VesselsNCT05669755 · start 2023-03-01 · primary completion 2027-09-01Phase 3Active Not RecruitingCardiovascular DiseaseNovo Nordisk A/S7101 participants
Show 19 more registered studies
StudyPhase · statusConditionsSponsor · size
A Research Study to See How Well CagriSema Helps People With Excess Body Weight Lose WeightNCT05567796 · start 2022-11-01 · primary completion 2024-10-30Phase 3Active Not RecruitingObesityNovo Nordisk A/S3400 participants
A Research Study to Compare Two Different Versions of Injectable CagriSema in People With Type 2 DiabetesNCT07357740 · start 2026-08-27 · primary completion 2027-08-25Phase 2WithdrawnWhy stopped: The study is withdrawn due to strategic reasons.Diabetes Mellitus, Type 2Novo Nordisk A/SEnrollment not listed
A Research Study to Compare Different Versions of Injectable CagriSema and Placebo in People With Excess Body WeightNCT07357766 · start 2026-06-22 · primary completion 2027-11-29Phase 3WithdrawnWhy stopped: The study is withdrawn due to strategic reasons.Overweight · ObesityNovo Nordisk A/SEnrollment not listed
A Research Study to Investigate the Effects of CagriSema Compared to Placebo in People With Type 2 Diabetes and Painful Diabetic Peripheral NeuropathyNCT06797869 · start 2025-01-29 · primary completion 2026-06-26Phase 2CompletedDiabetes Mellitus, Type 2 · Diabetic Peripheral NeuropathyNovo Nordisk A/S142 participants
A Research Study to Compare Blood Levels of Cagrilintide and Semaglutide After Single Doses of Different Versions of Injectable CagriSema in Adults With Overweight or ObesityNCT06716307 · start 2024-12-02 · primary completion 2025-03-28Phase 1CompletedObesityNovo Nordisk A/S18 participants
A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin, SGLT2 Inhibitor or BothNCT06534411 · start 2024-11-05 · primary completion 2026-06-02Phase 3CompletedDiabetes Mellitus, Type 2Novo Nordisk A/S1023 participants
A Research Study to See How Well Different Doses of CagriSema Help People With Excess Body Weight Lose WeightNCT06388187 · start 2024-06-24 · primary completion 2026-04-22Phase 3CompletedObesityNovo Nordisk A/S300 participants
Effects of NNC0194-0499, Cagrilintide, and Semaglutide Alone or in Combinations on Liver Damage and Alcohol Use in People With Alcohol-related Liver DiseaseNCT06409130 · start 2024-05-20 · primary completion 2025-11-21Phase 2CompletedAlcohol-related Liver DiseaseNovo Nordisk A/S270 participants
A Research Study to See if Kidney Damage in People With Chronic Kidney Disease and Type 2 Diabetes Living With Overweight or Obesity Can be Reduced by CagriSema Compared to Semaglutide, Cagrilintide and PlaceboNCT06131372 · start 2024-04-01 · primary completion 2025-09-24Phase 2CompletedChronic Kidney Disease · Type 2 Diabetes · ObesityNovo Nordisk A/S626 participants
A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in People With Type 2 Diabetes Treated With Once-daily Basal Insulin With or Without MetforminNCT06323161 · start 2024-03-26 · primary completion 2025-09-09Phase 3CompletedType 2 DiabetesNovo Nordisk A/S274 participants
A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in People With Type 2 Diabetes Treated With Diet and ExerciseNCT06323174 · start 2024-03-19 · primary completion 2025-10-01Phase 3CompletedType 2 DiabetesNovo Nordisk A/S189 participants
A Research Study to Look at How CagriSema Influences Food Intake, Appetite and Emptying of the Stomach in People With Excess Body WeightNCT06207877 · start 2024-02-23 · primary completion 2024-10-16Phase 1CompletedObesityNovo Nordisk A/S62 participants
A Study on How CagriSema Affects Levels of Atorvastatin and Warfarin in the Blood of Participants With Excess Body WeightNCT06289504 · start 2024-02-27 · primary completion 2024-10-16Phase 1CompletedObesityNovo Nordisk A/S34 participants
A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 InhibitorNCT06221969 · start 2024-01-16 · primary completion 2026-03-04Phase 3CompletedType 2 DiabetesNovo Nordisk A/S1024 participants
A Research Study to See How Well CagriSema Compared to Tirzepatide Helps People With Obesity Lose WeightNCT06131437 · start 2023-11-27 · primary completion 2025-12-08Phase 3CompletedObesityNovo Nordisk A/S809 participants
A Research Study to See How Well CagriSema Compared to Semaglutide, Cagrilintide and Placebo Lowers Blood Sugar and Body Weight in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 InhibitorNCT06065540 · start 2023-09-27 · primary completion 2025-11-19Phase 3CompletedType 2 Diabetes MellitusNovo Nordisk A/S2734 participants
A Research Study to See How Well CagriSema Helps People in China With Excess Body Weight Lose WeightNCT05996848 · start 2023-08-15 · primary completion 2025-01-06Phase 3CompletedObesity or OverweightNovo Nordisk A/S300 participants
A Research Study to See How Well CagriSema Helps People in East Asia With Excess Body Weight Lose WeightNCT05813925 · start 2023-04-03 · primary completion 2025-01-17Phase 3CompletedObesity or OverweightNovo Nordisk A/S331 participants
A Research Study to See How Well CagriSema Helps People With Type 2 Diabetes and Excess Body Weight Lose WeightNCT05394519 · start 2023-02-01 · primary completion 2025-01-28Phase 3CompletedOverweight · Obesity · Type 2 Diabetes MellitusNovo Nordisk A/S1200 participants

Registry check 2026-10-09 · Run this search on ClinicalTrials.gov

Human intervention studies

Selected studies in which participants received CagriSema, with their indexed or reviewed study type. Check the original article for the formulation, population and controls. Studies that only measured the molecule, or used it as a comparator, are listed separately below and are not counted as intervention studies.

  1. Human study · PubMed trial index Compound given to participants

    Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity.

    Garvey WT, Blüher M, Osorto Contreras CK et al. · The New England journal of medicine · 2025

    PMID 40544433 · DOI: 10.1056/NEJMoa2502081 · Registration NCT05567796

  2. Human study · PubMed trial index Compound given to participants

    Cagrilintide-Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes.

    Davies MJ, Bajaj HS, Broholm C et al. · The New England journal of medicine · 2025

    PMID 40544432 · DOI: 10.1056/NEJMoa2502082 · Registration NCT05394519

  3. Human study · PubMed trial index Compound given to participants

    Efficacy and safety of co-administered once-weekly cagrilintide 2·4 mg with once-weekly semaglutide 2·4 mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trial.

    Frias JP, Deenadayalan S, Erichsen L et al. · Lancet (London, England) · 2023

    PMID 37364590 · DOI: 10.1016/S0140-6736(23)01163-7

  4. Human study · PubMed trial index Compound given to participants

    Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2·4 mg for weight management: a randomised, controlled, phase 1b trial.

    Enebo LB, Berthelsen KK, Kankam M et al. · Lancet (London, England) · 2021

    PMID 33894838 · DOI: 10.1016/S0140-6736(21)00845-X

  5. Human study · PubMed trial index Compound given to participants

    CagriSema Reduces Blood Pressure in Adults With Overweight or Obesity: REDEFINE 1.

    Verma S, Böttcher M, Brown P et al. · Hypertension (Dallas, Tex. : 1979) · 2026

    PMID 41328546 · DOI: 10.1161/HYPERTENSIONAHA.125.26055 · Registration NCT05567796

Preclinical research, reviews & other publications

Animal studies, laboratory experiments, reviews and other indexed papers answer different questions. A review is secondary evidence; a case report does not estimate how often an outcome occurs.

No additional matching publication was retained. The search links below allow further investigation; they are not evidence that a study exists.

    CagriSema supplier sources

    Scientific sources describe molecules and experiments. The commercial links below identify recorded supplier packages. A publication or chemical database entry does not verify the seller, purity, sterility or contents of a lot. Some links are affiliate links; see our disclosure.

    No priced supplier offers are currently available in this catalog view. The research record remains available independently of stock.

    Reference sources & further reading

      The citations above link directly to publication records. Encyclopedia links are background reading and are not used to establish clinical effectiveness.

      Search for additional research

      These links run searches; their results have not been individually reviewed and can include unrelated compounds.

        Research information is not a dosing guide or a recommendation for personal use. Study findings are specific to the formulation, population and methods tested. Read our source and correction policy.

        Ingredient and related research

        Peptides

        Cagrilintide

        C194H312N54O59S2

        4409 g/mol · PubChem CID 171397054

        5 selected publications · 4 human intervention studies · 40 registered trials

        Protein / peptide · highest stage: Phase 3

        Structure, studies & sources →

        Peptides

        Semaglutide

        C187H291N45O59

        4114 g/mol · PubChem CID 56843331

        8 selected publications · 5 human intervention studies · 34 registered trials

        US: active ingredient of an FDA-approved medicine · Drugs@FDA

        Protein / peptide · highest stage: Approved in at least one jurisdiction (ChEMBL phase 4)

        Structure, studies & sources →